Medi Post.Co
1 known investors
Medipost is a biotechnology company focused on stem cell technology, including stem cell banking services and related research and development. It holds domestic and international patents and conducts government-funded research projects.
Also known as Medipost Β· λ©λν¬μ€νΈ
Investors Β· 1
Company profile
researched Aug 2026Medi Post.Co (λ©λν¬μ€νΈ, Medipost) is a South Korean biotechnology company focused on stem cell therapeutics and related services. Its first-generation stem cell therapy products are CARTISTEM, a treatment for knee cartilage defects in osteoarthritis patients, and PNEUMOSTEM, indicated for the treatment and prevention of bronchopulmonary dysplasia. A second-generation pipeline is built around the SMUP platform, including SMUP-IA-01, an injectable osteoarthritis treatment; SMUP-IV-01-DNP for diabetic nephropathy; and SMUP-IV-01-ARDS for acute respiratory distress syndrome.
Alongside therapeutics development, the company operates a stem cell bank and provides cell-storage services, and it has entered contract development and manufacturing work, including a CDMO agreement covering hiPSC-based dermal papilla cell culture medium. The company reports a portfolio of domestic and international patents and participation in national research projects, and it maintains a US subsidiary involved in clinical development in the American market.
Business model
Revenue is generated from stem cell therapeutic products, stem cell banking and cell-storage services (including conversion services offered with partners), and contract development and manufacturing agreements.
Traction
Company-reported figures include more than 95 domestic and international patents, more than 38 national research projects performed, 337,956 stem cell bank storage cases, and research and development personnel representing 44% of staff. First-half 2026 separate revenue was reported at KRW 41.3 billion.
Latest developments
In 2026 the company signed a CDMO agreement with Qstem covering hiPSC-based dermal papilla cell culture medium, reported first-half separate revenue of KRW 41.3 billion with continued operating profit, and partnered with Woongjin Preed Life on a new cell-storage conversion service. CARTISTEM enrolled and dosed its first patient in a US Phase 3 trial after the FDA allowed a single pivotal trial, and the product transitioned to a domestically produced culture medium intended to improve safety, production cost and yield.
βΈFull profile β technology, geography
Technology
The company's activity centers on mesenchymal/stem cell-based therapeutics, with a first-generation portfolio (CARTISTEM for knee cartilage defects; PNEUMOSTEM for bronchopulmonary dysplasia) and a second-generation SMUP platform spanning injectable and intravenous candidates for osteoarthritis, diabetic nephropathy and acute respiratory distress syndrome. Related capabilities include stem cell banking and induced pluripotent stem cell (hiPSC)-based cell culture medium development for contract manufacturing.
Geography
Headquartered in South Korea, with a US subsidiary supporting clinical development and market entry in the United States.
Compiled by commissioned research from 4 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 7
launches, deals, and filingsMedipost signed a contract development and manufacturing agreement with Qstem covering hiPSC-based dermal papilla cell culture medium.
The company reported separate revenue of KRW 41.3 billion for the first half of 2026 and stated that its operating profit remained positive.
The company partnered with Woongjin Preed Life to provide a new cell-storage conversion service.
The company concluded a customized on-site education program on advanced biological medicinal products organized by Korea's Ministry of Food and Drug Safety.
CARTISTEM began US Phase 3 dosing with its first enrolled patient as part of the company's entry into the US market.
The company converted CARTISTEM production to a Korean-made culture medium, citing strengthened safety, lower production cost and improved yield.
Press coverage reported that the FDA permitted CARTISTEM to complete US development with a single Phase 3 trial.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 4
primary sources listed
- Medi Post.Comedi-post.co.kr Β· web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medi Post.Co do?
- Korean biotechnology company developing stem cell therapeutics and operating a stem cell bank.
- Who are Medi Post.Co's investors?
- Medi Post.Co's investors include Atinum Investment Co. Ltd..